 | The application and versatility of medical imaging modalities are continuing to grow in significance as the population ages and healthcare costs rise. Examinations that can facilitate earlier disease diagnosis and the most appropriate treatment are in order. This bodes well for contrast media markets. |
|
| As Kalorama Information's lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived. But is healthcare ready? Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to be fully utilized, and those companies willing to pivot strategies and best adjust to tomorrow’s healthcare marketplace may be rewarded. |
|
| Diagnostic tests are an essential tool for confirming the health status of animals. The global impact of diseases such as bovine spongiform encephalopathy, foot and mouth disease, and highly pathogenic avian influenza has revealed that diagnostic tests play a key role not only in facilitating safe trade but also in many other areas such as the early detection of new diseases and the control of exotic or enzootic animal diseases. |
|
| What does the diagnostic market look like today, how is the continuing economic news effecting the market, and what are companies doing right now to prosper? This diagnostic industry market research bundle, with over 1,200 pages, seeks to answer these questions and provide market watchers with the most comprehensive view of the industry. |
|
| The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. |
|
| At their most basic level, wellness programs represent an attempt to encourage good health and thereby decrease utilization of health care products and services. They have evolved out of necessity from the current U.S. health care system, in response to a variety of factors including continually rising costs of care and declining quality of life. |
|
| With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. |
|
| The healthcare information technology (HIT) market was in a growth trend prior to the recent recession. While economic times have tightened budgets some, there is still opportunities for companies in this market.
In this report, Kalorama takes a comprehensive look at the demand for IT products in the healthcare market - with a focus on computer systems for hospitals, nursing homes, physician offices and other healthcare entities. Kalorama has interviewed experts in the HIT industry and presents the latest findings on where the industry is headed. There is tremendous excitement in HIT given the commitment to healthcare investment among healthcare entities and some of the Obama Administration incentive programs; but there is also increased competition. |
|
| This report analyzes the current and potential world market for medical MRI and ultrasound systems. This report generally reviews the nature and direction of research, as well as future markets for two key areas of imaging technology: Ultrasound and MRI. the report includes the following as part of its market coverage: |
|
| !The ubiquity of infections makes thier detection a healthcare priority and an ongoing opportunity for IVD companies. The aging of the population, and emerging threats - MRSA, swine flu, and others have had an impact on this market recently and will continue to in years to come. Kalorama Information has been observing diagnostic markets for over a decade and has assembled in this report, Infectious Disease Diagnostics, Kalorama Information has assembled its best primary and secondary research. This report focuses on products used for the diagnosis of bacterial and viral infections. The major consideration is given to bacterial infections because (a) they are the most frequent type of infections, and (b) the practical aspects of diagnosis and therapy are more meaningful based both on medial considerations and on market considerations. On the other hand, viral infections are becoming of greater importance due to (a) the discovery of new viral infections, (b) advances in the development of viral therapeutics, and (c) the mutation viruses that cause drug resistance. |
|
| The recession will have an impact on any elective medical procedure, and dental implants (and the resulting bone grafts) are no exception. Since the last edition of Kalorama Information's Implant-Based Dental Reconstruction: World Dental Implant and Bone Graft Market, economic conditions have changed in US and world markets, but the industry has also changed: mergers, new products, an increase in computer design and trained dentists are driving growth, as is reimbursement. |
|
| Biosimilars, or generic biologic drugs, are marketed around the world but still restricted in the U.S. This may soon change, and Kalorama Information has released this timely study of the market in Europe and other areas in the world and the possibility of a U.S. Market in the near future. |
|
| Since the last edition of Kalorama Information's <i>DNA Sequencing Equipment and Services</i> report, the market has been changing in unpredictable ways as second-generation sequencers are being incrementally introduced and upgraded. On the surface, the situation has become somewhat linear and predictable, but as Kalorama Information biotech analyst Justin Saeks explains, it is actually a unique and relatively volatile situation that is not seen often with life science tools markets. Third-generation systems have the potential to completely change the market, or to simply join the pack. |
|
| The healthcare information technology (HIT) market was in a growth trend prior to the recent recession. While economic times have tightened budgets some, there is still opportunities for companies in this market. In this report, Kalorama takes a comprehensive look at the demand for IT products in the healthcare market - with a focus on computer systems for hospitals, nursing homes, physician offices and other healthcare entities. Kalorama has interviewed experts in the HIT industry and presents the latest findings on where the industry is headed. There is tremendous excitement in HIT given the commitment to healthcare investment among healthcare entities and some of the Obama Administration incentive programs; |
|
| This country of 1.3 billion people is now America’s sixth largest export market, and India’s economy, while showing some effects of the world recession, has been less impacted than other nations and is showing growth, although not as rapid as in recent years. |
|
| The information represented in this report is a comprehensive analysis of the eye care market globally with a special focus on the United States and selected international sectors. The year ending December 31, 2008 was used as the base year with forecasts to the year 2013. Market statistics are given in U.S. dollars and in units [where appropriate]. Basis for the market analysis consists of key data, statistics; references, and information from a large data base of primary and secondary research sources documented in the report consisting of interviews, professional meetings; conferences; presentations; journals; consumer media [radio, TV, magazines, newspapers]; and Internet content involving more than 40,000 sources. Data were collected for global populations and medical providers who represent the key influences in the eye care market. |
|
| Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is a $35 billion industry and expected to grow as much as ten percent per year. |
|
| Kalorama Information's 300 page Worldwide Wound Care: Total Market Coverage report represents the full contents of the Kalorama three-volume 2009 wound care series. The reports are joined in one volume to offer a better value to the customer that wants total market coverage. Kalorama's approach differs from other published reports in that we segment the world wound care market by application: skin ulcers, burns and surgical/trauma wounds. Wound care is a vast market and this approach ensures that customers can see revenues, products and market share for the part of the market most relevant for their business. |
|
| There are millions of surgical procedures performed annually worldwide and the market for wound care products and techniques is significant. Surgical and trauma wounds are, by far, the most common types of wounds addressed in the wound care area and thus an important market.Kalorama Information's Wound Care Series offers one of the most complete market round-ups published recently, featuring the following: * This is the only recently published market research study to provide Wound Care Revenues by Condition/Treatment. This report, for instance identifies only those anti infective or biological dressing revenues used for surgical wound treatment. (Other volumes in the series address Burns and Skin Ulcer revenue). * Forecasts to 2013 are provided for each market segment. * A focus on products but also on the marketing behind those products, essential knowledge for operating in the wound care market. * Analyst insight into this market; Kalorama Information’s Wound Care Markets Series takes an objective view and avoids product hype. * Breakdown of Worldwide Revenue Share by Region (U.S., Europe, Japan and Rest of World) |
|
| Who is Who in Clinical Diagnostics in China, produced jointly with the firm McEvoy & Farmer, is the product of on-the-ground primary research on Chinese labs conducted in fall and winter 2008. Included in this report: Market Size Estimate by Major Category (Chemistry, Critical Care Chemistry, Urine Chemistry, Hematology, Flow Cytometry, Coagulation, Immunochemistry, Molecular Testing, Other IVD) Country Industry Overview Chinese Hospital Statistics Profiles of 42 International Diagnostic Companies with operations in China Profiles of 130 Domestic Diagnostic Companies Profiles of 24 Local Distributors, indicating the companies they distribute for |
|
| New technologies are transforming patient monitoring and Kalorama Information has reported on these developments last year. This report, High-Tech Patient Monitoring market updates revenues and segment breakdowns to reflect changes in the market, particularly the remote monitoring and the enhanced role of applications to transfer patient data to EMR systems. Advances in remote patient monitoring include new peripherals, real-time audio and video for “face-to-face” interaction between clinicians and patients, wireless communication, systems that “sort” the vast amount of data collected in order to put it into the context of a patient’s condition, portable and ambulatory monitors, web-based access to the patient record, systems that transfer data to an electronic medical record (EMR), and full-service outsourcing that includes a clinician to evaluate data and send a report to the attending physician. |
|
| As Kalorama Information has examined the markets for year, we have seen the companies whose approaches have succeeded and those who have not been successful. A small pivot in strategy often may have made the difference. We have summed up this knowledge in What is Working in IVD: Successful Commercialization of New Products and Technologies The report is written by Kalorama's lead diagnostic expert, Shara Rosen, R.T. M.B.A., author of six best-selling editions of the industry's leading market research report in IVD diagnostics The Worldwide Market for In Vitro Diagnostic Tests. Rosen offers tips gleaned from years of watching the market - keys to successful new product launches in the industry as t is now. |
|
| It is commonly asserted that in vitro diagnostics is a recession-proof industry. Kalorama Information's lead diagnostic analyst Shara Rosen tests that assumption and provides strategic conclusions in Shara Rosen's new report In Vitro Diagnostics in a Recessionary Economy. The economic problems that began slowing the U.S. economy keep spreading, with Europe and Japan following America into recession. The US is experiencing high unemployment rate and increased numbers of uninsured workers. But what impact is the downturn having on in vitro diagnostic companies? What are the best areas of IVD and the best world markets? How should companies price and market their products? What are key companies in the market doing at this time? |
|
| The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions. This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013. |
|
| The outbreak of H1N1 (swine flu) highlighted the public health importance of improved testing techniques and providing market opportunities for manufacturers of diagnostic tests and other products related to the disease. These conclusions and others appear in a new report released from Kalorama Information: Swine Flu Market Alert by Kalorama's lead analyst, Shara Rosen. |
|
| The multi-billion veterinary health products market, though smaller in opportunity as compared with the human health sector, offers significant return on investment, primarily driven by lower risk and faster product development cycles. The veterinary health products market has remained resilient over the economic downturns of the past 2 decades. This report, World Veterinary Health Products, takes a look at veterinary health products for both companion (pet) animals, and production animals (livestock and poultry) and the opportunity for existing players and new entrants in three segments:Pharmaceuticals (including Parasiticides, Anti-infectives, NSAIDS, Cardiovasculars, Hormones, CNS, Others) Veterinary (Pet) OTC Products (Parasiticides, NSAIDS, Vitamins, GI Disorders, Cold and Cough, Others) Performance Enhancers Veterinary Vaccines |
|
| While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's <i>Rx to OTC Switches 2009,</i> we take a look at recent swtiches, products that may switch in the future, and categories that can benefit most from an OTC product. |
|
| Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. |
|
| Cell culture is a major foundation of biopharmaceutical development, bioprocessing and manufacturing. As the biopharmaceutical market grows, so should interest in the cell culture products market. Biopharmaceutical products are developed from large, complex protein molecules, which require equally complex manufacturing methods and an array of analytical techniques. As growing cells for biopharmaceutical production is slow, expensive and complicated, optimizing cell culture development is of paramount concern to companies developing biopharmaceuticals. |
|
| Pharmacodiagnostics are considered the pathway to what has been termed "personalized medicine," the use of molecular analysis to achieve optimum medical outcomes in the management of a patient’s disease or predisposition to disease. As such, personalized medicine promises to bring about a new standard of healthcare, with the possiblity to increase profits, speed clinical trials, achieve better clinical results and satisfy patients. But how can companies earn revenue in this undertaking? What are the likely challenges for pharma companies and IVD companies? Will the current eocnomy impact this emerging market? |
|
| Wound care is a constantly changing market. New wound care products and devices are entering the market with quickly to treat the most painful and critical of injuries, all striving for the best clinical outcomes. Kalorama's Wound Care Markets, 4th Edition, Vol. II: Burns represents the fourth time that Kalorama has rexamined this aspect of the wound care market, and the study analyzes burn treatment in wound care in the following product segments and subsegments: : |
|
| Market numbers reflect the change in reimbursement for skin ulcers for hospitals and nursing homes that went into effect in October 2008!Wound care is a constantly changing market. The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. Kalorama's Wound Care Markets, 4th Edition, Vol. I: Skin Ulcers. represents the fourth time that Kalorama has rexamined this aspect of the wound care market, and the study analyzes the market using the following product segments and subsegments: |
|
| This report provides the reader with an overview of the medical beds and medical chairs industry and the trends driving growth. Medical beds include all hospital types of beds including mattresses and overlays.The term medical chairs can refer to many different types of chairs including ENT chairs, examination chairs, blood drawing chairs, cardiac chairs, dialysis chairs, ophthalmic chairs, surgery chairs and many more. For the purposes of this report, only rehabilitation chairs and wheelchairs are considered in the market coverage. |
|
| This Kalorama report, Contract Manufacturing in Orthopedics Devices: Markets for Hip and Knee Implants provides market size and forecast for the most utilized orthopedic devices. A global report, the business is calculated and forecasted for the United States, Europe, Asia and Rest of World. This report should be of interest to both the established and new entrant CM’s that are engaged in customer retention with existing revenues and established business, or generating new revenue streams from the high growth medical device global marketers. |
|
| Point of care diagnostics is one of the most dynamic parts of the diagnostics industry and an area where several major competitors are battling for market share. Point-of-care testing (POC) is defined as diagnostic testing at or near the site of patient care. Over the years, the increasing introduction of transportable, portable, and handheld instruments has resulted in the migration of POC testing from the hospital environment to a range of medical environments including the workplace, home, disaster care and most recently, convenience clinics. |
|
| From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama's leading diagnostic analyst, Shara Rosen. |
|
| The dialysis industry enjoys a unique place in the healthcare sector. The industry encompasses two very lucrative segments -- the medical device industry (dialysis products and supplies segment) and the healthcare services industry (dialysis services segment). |
|
| The pharmaceutical market in India ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be essential for pharmaceutical companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This report Pharmaceutical Market in India provides market watchers with needed information on this growing market, including: |
|
| Current economic conditions dominate business strategies. While healthcare has fared better than other industries, it will not be immune from the effects of the current recession. But what aspects of healthcare will be impacted? How much of spending will be out of the consumer's pocket? How will some novel trends (retail clinics, medical tourism) fit into this economy? It is commonly asserted that OTC and generic drugs sales will be boosted. Will this pan out? What will be the possible effects of various types of healthcare plans that might be implemented? |
|
| The appearance of in-store health clinics is a significant trend for pharmaceutical and POC diagnostic market watchers, as well as for those in retail. When last Kalorama published the first syndicated market research study on the emerging trend of in-store clinics in 2007, retail clinics were a novel trend. Now, with a few years of activity, they are established in food, drug, mass merchandizing and other stores, with both successes and failures. There is growth in some projects, scalebacks in others. Kalorama has analyzed these developments and returned to examine the state of the market in 2009. |
|
| The liquid chromatography (LC) market has been relatively mature for quite a while, with a slow evolution of products and applications over the last few decades. High performance liquid chromatography (HPLC) has used essentially the same types of components since the 1980s. However, the market has seen an extraordinary amount of technological change in the last few years as companies have continued to introduce new systems performing fast LC and ultra HPLC (UHPLC). |
|
| Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S. Congress has also indicated a desire to move forward with stem cell research. The momentum in two branches of American government, along with scientific developments and the competition of world markets presages good market conditions for stem cell research. |
|
| Kalorama Information has been watching medical device markets in 2008 and has produced several market research studies useful to companies operating in this market.To maximize market research dollars, we've assembled one PDF that contains five critical research studies with market forecasts, product reviews, company profiles and other information regarding these marketsThe following medical device topics, representing 1,115 pages of information, the best of our 2008 market research, is included in this bundle. * Infusion Pumps (includes Ambulatory, Disposable, Syringe and Special Pumps) * Catheter Markets (Urological, Intravenous, Cardiovascular, Oximetry and Wound Drainage Catheters) * Minimally Invasive Devices * Reusable Medical Device Markets * OEM Contract Manufacturing in Finished Products (Forecasts or OEM contract manufacturing revenue by categories of medical devices) |
|
| Electronic Medical Record (EMR) is the bread and butter concern of the health information technology marketplace. Government initiatives and cost concerns are key drivers of EMR and will continue to drive purchases of EMR systems in the near future. Technologies such as patient monitoring systems and handheld devices will need to adapt to EMR systems to thrive. Those seeking to understand the health IT market will need to build products that address the need for EMR, or work around existing systems and an understanding of EMR products in the marketplace is critical. |
|
| The reinvigorated market for medical imaging systems employing x-rays has undoubtedly been propelled by the explosion of digital technology. But also, the expanded role of imaging modalities in a whole host of clinical applications from trauma to cancer to cardiology has increased the profile of radiography while enabling computer technologies expand the usefulness of traditional x-ray techniques. |
|
| Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine. |
|
| This Kalorama Information report - Clinical Nutrition - focuses on three primary segments of essential medical nutrition: * Infant Nutrition * Enteral Nutrition * Parenteral Nutrition |
|
| Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories: |
|
| A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections). |
|
| The gastrointestinal endoscopy market is a market on the rise. With continually advancing technologies available and world population increasing every year, the gastrointestinal endoscopy market.Market Driven by Aging Population, Growth in GI Disease CasesGrowth in this market encompasses many areas with surgery being the majority of the increase. Cancer is one of leading reasons for surgery with more than 1 million new cases of colon/rectum cancer reported each year around the world. |
|
| This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. |
|
| Dominated by Lab Corp and Quest, the clinical laboratory services market is growing as new competitors enter. An essential part of the health industry, it is estimated that approximately 80% of physician’s diagnoses are a result of laboratory tests. In addition to diagnosing patients, clinical lab testing is performed to evaluate disease progression, monitor drug treatment and conditions, determine individual therapy, and several other reasons. Those seeking to enter this business or to know more about it will benefit from Clinical Laboratory Services (Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles), an overview of the clinical laboratory industry and the trends driving growth. Included in the report are statistics influencing the industry, incidence of diseases in the U.S., demographics; life expectancy, and company strategies. |
|
| The substances utilized for what is commonly referred to as 'protein therapeutics' have one thing in common --- they are all composed primarily of á-amino acids; and these á-amino acids are linked together by a distinct chemical bond known as a “peptide” bond. Used in a variety of areas of medicine, they are among the most interesting pharmaceutical markets. |
|
| It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. |
|
| Biophotonics describes the use of photonics in biomedical applications. There are several key areas that are associated with biophotonics. All of these center on microscopy and related technology. The reason that this is so is that biophotonics look at biological functions at the cellular level, or even smaller. The only way that these processes can be observed is via one or another form of microscopy. |
|
| Often what separates successful marketing from bad is good competitive intelligence. This is true in life sciences as much as other industries. Many companies approach CI in a way that is unplanned, indirect and harmful to their business. But how does one know if they are conducting their company's CI in the best way? |
|
| Genetic Technology is one of the closest-watched areas in healthcare and in the past two years Kalorama Information has published major studies on different aspects of this market. This Kalorama Information Bundle consists of four major reports in biotech equipment: * DNA Sequencing Equipment Markets: Markets, Forecasts, Sequencer Product Reviews and Company Profiles * SNP Genotyping Markets: Single base pair mutations that occur at a specific site in the DNA sequence, the most common type of genetic variation between human beings. Because they are responsible for over 80% of the variation between two individuals, SNPs are ideal for the task of hunting for correlations between genotype and behavior or quality exhibited by a living organism. * Gene Expression Profiling Markets (Coverage of Gene Expression in Biomarkers, Pharmacogenetics / Pharmacogenomics, Infectious Disease Research, Cancer Diagnostics and Prognostics, and Diagnosis and Prognosis of Other Diseases * Analytical Chip/BioChip Markets (Includes Lab on a Chip, DNA/Gene, Protein, and other Microarrays) |
|
| Hernia repair is a standard part of general surgery, but nonetheless one that has been revolutionized by two events over the past decade and a half: the the development of tension-free and laparoscopic techniques and the use of prosthetic materials. |
|
| Fueled by the aging population in the US, Europe and Japan, blood markets have shown continued growth and should continue to do so near-term. There are many aspects to the blood market: blood products, testing, blood equipment, and synthetic products. In one volume, a single comprehensive evaluation Kalorama Information's Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products of the blood industry provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. |
|
| Reusable medical instruments and devices are products that are sterilized or cleaned for reuse. Advances in medical sciences and, in particular, minimally invasive surgical and diagnostic procedures, have stimulated the development of new and improved medical devices. This is due to developments in engineering and material sciences. The design for reusability is important in an effort to provide cost effective healthcare. |
|
| Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. |
|
|
| The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology. |
|
| Contract Manufacturers seeking to partner with global marketers can find the best opportunities making the medical devices that drive the best sales and growth for global marketers. This report covers contract manufacturing (CM) in several medical devices that show promising growth for the next five years. |
|
| Infusion pumps are used to infuse necessary fluids, which includes medications and/or nutrients, to a patient’s circulatory system. Infusion pumps are often used in situations where continuous monitoring and treatment by a nurse or other health staff would be expensive, impractical, or unreliable. |
|
| Minimally invasive surgery (MIS) allows doctors to perform many complicated operations with a short hospital stay. It is a safe, feasible, and patient-friendly method of performing an operation.The report includes product information, procedure volume data, world demographics; and other general issues affecting the MIS device market. Information is presented as a worldwide overview, with a focus on the US. A market summary includes market analysis by intended use and a competitive analysis of leading providers. |
|
| Over 1400 of cutting-edge research detailing the most important markets in today's diagnostic industry!Three in One Report Bundle! Combined these reports would be over $11,000 (single user license). As a bundle these reports are available for over 30% off cover price - $7,995.The purpose of the Kalorama Key Topics Bundles is to allow companies to stretch their market research budget by providing multiple related reports, each available for sale on their own, together in one offering at a significant value.This Worldwide Diagnostics Market Research Bundle represents three of our most innovative and best-selling topics related to the Diagnostic Industry today: We’ve included the following reports, each of them relevant to understanding the diagnostic market in 2008: |
|
| The market for respiratory disposables and reusable accessories is witnessing dynamic changes. The market factors influencing demand in the U.S. are also present in Europe and the Asia/Pacific region — the aging of the population, technological trends and society’s acceptance of people with disabilities. Kalorama's World Market for Respiratory Equipment and Disposables represents the third time that Kalorama Information has tackled this important device market. |
|
| Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study. |
|
| Test services, once the norm in the diagnostics industry, then abandoned for reagent sales, are now making a comeback.IVD companies have established cGMP and CLIA-registered labs by which they offer their proprietary tests to physicians, hospitals and reference labs. These tests are outside the oversight of the traditional FDA and CE Mark test commercialization avenue in the U.S, and Europe and so are thought to come to market by what may seem to be the back door. |
|
| The aging of the population, namely the baby boomer demographic segment is driving the market for facial rejuvenation products. The size and wealth of this aging segment and its overwhelming desire to retain a youthful appearance are driving growth for aesthetic procedures. |
|
| The benefits of automation in the clinical laboratory are well documented. They involve replacing manual, potentially dangerous, error-prone steps with automated processes requiring minimal operator intervention. This approach can increase productivity, decrease turnaround time, improve staff safety, minimize errors, improve the handling of specimens, and allow labs to reallocate personnel to more important and productive tasks. |
|
| This Kalorama Information report, Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) is truly a real-world guide to the potential market for companion diagnostics.Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as an important growth strategy in both the diagnostic and pharmaceutical industries. It is envisioned as a pathway to personalized medicine, where the right therapeutic is selected for the right patient. Personalized medicine is one of the key trends in healthcare, and it's no surprise that there is great enthusiasm in many quarters of the in vitro industry, pharmaceutical companies and the investment community about companion diagnostics. But will the concept work in the fashion that the industry is envisioning? Who will succeed and with what strategy? How much can companies expect to earn in this field? What strategies should companies adopt to thrive in this market? |
|
| SNP Genotyping and Analysis Markets is one of the cutting-edge market research reports available at Kalorama Information.com. If you have not yet registered on Kalorama Information.com, be sure to do so to view report TOCs, and sign up to get updates as new Kalorama biotechnology and medical market research titles are published. |
|
| For companies seriously competing in the healthcare market, having up to date market information and important trends is crucial. Kalorama Information publishes high quality market research on the important and profitable sectors of the healthcare market, including: pharmaceuticals, biotech and diagnostics. Now, all of Kalorama Information's upcoming reports are available in an annual subscription at a special price. Additionally, the offering includes the entire historical backlist of Kalorama's past publications in a searchable format. This subscription product includes:* All of Kalorama’s Reports for One Year Forward from order date.* At least 43 Market Research Reports (almost $400,000 value) in the Pharmaceutical, Diagnostic and Device Fields for One Low Price.* Plus the entire contents of the Kalorama library (estimated 300 Reports, 61,970 pages).* Tens of thousands of figures and tables.* Web based with Search function.* Global Site License, can be used on any company computer.* Low $75,000 1 year subscription. |
|
| Countries covered: United StatesAs Kalorama publishes its second edition of this detailed report on the long term care industry and all of its segments, there is no decrease in demand or activity for everything from nursing homes, to home care, to hospices. The U.S. long care industry has experienced strong growth from 2002 through 2007 and this growth is expected to accelerate through the forecast period as the U.S. population continues to age and demand rises for long term care. Ongoing cost containment will continue to pressure both private and public managed care organizations, however, new premium-priced specialty services such as dementia care and upscale living options will create growth opportunities. |
|
| Countries covered: China, India, RussiaPharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. |
|
| This completely updated edition of Kalorama’s comprehensive and indispensable report covers the breadth of traditional IVD testing. The report contains complete market statistics and analysis for all areas of IVD, including: * Point-of-Care * Core Lab * Immunoassays * Molecular Assays * Hematology * Coagulation * Microbiology and Virology * Blood Banking * Histology and CytologyMarket size, growth, share, and geographic distribution, as well as trends in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Projections are made through 2012. |
|
| Since the arrival of drug-eluting (called drug-eluding by some) technology a few years ago with the promise of reducing restenosis, questions abound surrounding the future of the stent market: After numerous clinical studies and mixed cost-effectiveness results, how is drug-eluding technology expected to peform in the future? What can companies do to best market this technology in the healthcare system of the US and 6 other major world markets? What are the market trends to watch that will determine growth in this field in the coming years? What companies have already established a leadership position in stents and what do start ups have to do to join them? Major World Markets for Stents and The Economics of Drug Eluding Technology, written by Kalorama Analyst Dr. Kenneth Krul, takes a hard look at these questions with economic analysis unmatched by any resource. |
|
| 2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations. Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market. |
|
| 2008 has not seen any letdown in the use of wireless technologies in healthcare settings. The clinical environment is a highly mobile one, and physicians, nurses and other clinical operators have a real need for fast information they can act upon. Wireless technologies fit healthcare well. It's therefore no surprise that hospitals are dedicating large portions of current and future budgets to IT development and wireless is likely to be among their choices. Kalorama’s Wireless in Healthcare 2008 is your guide to the still growing market for wireless healthcare applications in the United States and globally. This report contains explanations that cut through the confusion surrounding these technologies and provide readers with a total picture of wireless in healthcare. |
|
| Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well for OTC products. For the purpose of this study, Kalorama Information has divided products into five general segments: * Analgesics * Allergy, Cough, Cold, Flu Remedies * Gastrointestinal Remedies * Dermatologics * Others (including: Smoking cessation products, Sleepaids, Dental rinses, fluorides, Hair growth remedies, Diet aids) |
|
| 2008 has seen no decrease in attention on wound care products. The aging of the population and a constant demand for products that speed healing and improve outcomes drives the wound care industry. For market watchers, this makes for a dynamic market that has changed in recent years with biological developments. Kalorama Information's analyst Mary Ann Crandall has reviewed the Wound Care Industry in several editions of wound care market reports and has participated in industry panels. Kalorama Information's three-volume Wound Care Markets series examined three segments of wound care - skin ulcers, burns, surgical trauma. World Wound Care Markets 2008 takes an all-encompassing view of the wound care market. |
|
| Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies four years ago, there has been much more worldwide involvement in the development of the biogeneric arena. |
|
| Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the market for prescription drugs likely to switch in the following drug categories:# Allergy and Cold# Antilipidemic Agents# Fungal Infections# Gastrointestinal Drugs# Hair Loss Treatments# Migraine Therapy# Nonsteroidal Anti-inflammatories# Oral Contraceptives# Osteoporosis and Hormone Replacement Therapies# Overactive Bladder# Sexual Dysfunction# Sleep Agents# Smoking Cessation# Viral Infections# Others |
|
| Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first successful cancer vaccine product, Merck's Gardasil, has had dramatic and surprising results. Other products also exceeded revenue expectations. The competitive dynamics have changed with merger activity, and many new products are on the way. |
|
| Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. |
|
| Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. |
|
| With their ability to differentiate and become an ongoing source of cells that make up critical tissues and organs, stem cells have potential for new regenerative therapies and as new research tools for drug developers to test emerging therapies on diseased cells.For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the market. Kalorama Information has tackled that question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells: |
|
| Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the market for prescription drugs likely to switch in the following drug categories: |
|
| Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence cancer diagnostics? These questions and more are answered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition. Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information's Worldwide Market for Cancer Diagnostics, 3rd Edition represents the third time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. |
|
| Novel technologies in patient monitoring are emerging to meet the increasing demands of an aging population, decreasing healthcare resources, and an emphasis on reducing hospital days. Nearly all focus on some form of ambulatory monitoring using wired or wireless technologies.It is no longer satisfactory for a system to simply monitor a patient's vital signs. Advances in remote patient monitoring include new peripherals, real-time audio and video for “face-to-face” interaction between clinicians and patients, wireless communication, systems that “sort” the vast amount of data collected in order to put it into the context of a patient’s condition, portable and ambulatory monitors, web-based access to the patient record, systems that transfer data to an electronic medical record (EMR), and full-service outsourcing that includes a clinician to evaluate data and send a report to the attending physician. |
|
| Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure. |
|
| Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. |
|
| Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. |
|
| For 12+ years, the team of Carl McEvoy and Michael Farmer have conducted exhaustive on-the-ground research in Asia, and most notabably China, interviewing lab employees and executives to obtain an accurate picture of the IVD market in China and other countries. In cooperation with Kalorama Information this report Molecular Diagnostics in China, is the definitive measure of PCR testing in China. |
|
| Catheters are among the world's oldest medical devices, but yet they are still critical part of the practice of medicine and surgery. Companies seeking opportunities in this medical device market will want to utilize Kalorama Information's World Market for Catheters. This report is a comprehensive look at the market of these critical medical devices. Which segments of catheters are growing the fastest? Which are most profitable? Who are the key players and what share do they have of the market? What are the critical issues and trends that will drive catheter sales in the future. What pitfalls do manufacturers need to be aware of? These questions and more are answered in this report. |
|
| One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. |
|
| There is over a 30 billion dollar market for technology companies who assist the healthcare industry meet its challenges. This report is a combination of 5 Kalorama Information Market research reports - over 1100 pages of material. This report details the 5 areas Kalorama thinks will be the most promising markets for technology in healthcare. |
|
|
|
| Parts of the gene expression analysis market continue to develop in a somewhat predictable manner, whereas other segments are becoming increasingly complex and volatile. The main products—microarrays and RT-PCR—continue to gain widespread acceptance and to see revenues grow rapidly. However, different products and applications are increasingly being introduced, making the market more fragmented as well as unpredictable. In terms of application, too, the landscape is shifting. Although life-science research is still the dominant application, the clinical diagnostics and prognostics market is also becoming a reality. |
|
| Improved surgical techniques and organ preservation, understanding of immunologic barriers, and the development of newer and more potent immunosuppressives have combined to improve survival of transplant patients and grafts. Rejection remains the major barrier to long-term graft survival in patients, organ transplantation therapy is highly dependent on the success of immunosuppressants to suppress the recipient’s immune responses to the foreign organ. |
|
| While insurance is the most common form of payment for healthcare services, increasingly customers are paying for their own expenses. Pharmaceutical, device and diagnostic companies, should recognize that a part of their revenues are originating directly or indirectly from out of pocket expenditures. Health care costs are high and accelerating as a result of a confluence of factors within the broader economy, as well as the health care marketplace. Unique financial services have been created to facilitate non-insurance-paid health care services, and more are expected to be created in the near term. |
|
| Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are also at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. |
|
| Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for developing regions to grab a piece of the clinical trial market. |
|
| Contract Manufacturers are finding opportunities with managers located at OEM corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. |
|
| Cell analysis is not a new laboratory procedure. Clinical diagnostics using cells and tissues is one of the oldest disciplines in laboratory medicine. Histological study of biopsy samples, the complete blood count, and the enumeration of disease-bearing cells have been used routinely for at least 60 years. In many ways, these disciplines had changed little until the 1990s. What's new, however, is the myriad of combinations of tests and technologies that come together to create a new map of cell diagnostics. |
|
| Analytical microchips can be considered one of the fastest growing technology segments in life sciences. The range of applications to which these miniature laboratories may be directed is very broad — covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. |
|
| As one of the most competitive pharmaceutical markets, keeping track of the cardiovascular drug market can be a difficult undertaking. The range of therapeutic options available to physicians has expanded significantly in the past few years, and will continue to increase with a robust pipeline.
Kalorama's 2nd edition of The World Market for Cardiovascular Drugs Market is designed to steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. |
|
| For food ingredient companies willing to enter the non-food market, there is over a billion dollars of market potential awaiting them. In addition to increasing the profitability of their traditional product lines, producers of ingredients can potentially expand their markets by moving their products or byproducts into the healthcare sector, where drug producers or manufacturers of some biomedical devices could incorporate them into their products. |
|
| Abundant opportunities are available for manufacturing companies who enter the outsourcing medical device manufacturing market; but the market is competitive and information has been hard to obtain. Original equipment manufacturers (OEMs) are finding opportunities with managers located at the corporate headquarters or main manufacturing/assembly operations as they take a hard look at costs and seek outsourcing for cost efficiency. Kalorama's OEM Contract Manufacturing in Medical Devices Series presents a total study of market for outsourcing in medical devices. It features an exhaustive three-way market segmentation: It looks at the OEM market revenues by therapeutic area, as well as by segment of device manufacturing. And it also includes revenues by the general device classifications (commodity/non-commodity). This allows those looking at this growing market to get a complete picture of the OEM market. |
|
| Retail clinics, also known as convenience clinics, represent a disruptive innovation into the U.S. health care market, which evolved from and is uniquely positioned to benefit from the health care system’s shortcomings. These clinics present a new opportunity for retail outlets to earn more revenue from rents and 'indirect' revenues from sales to the retail store as a result of a clinic visit. But there is also an opportunity for diagnostic and pharmaceutical companies to capitalize on this trend. |
|
| In five years, Kalorama Information believes the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will increase demand for drug decisions to be made at the pharmacist level. This report, Prescribing Pharmacists, a Decision Maker Emerges details the reasons behind this change and defines the roles of the new decision makers that pharmaceutical companies will have to incorporate into strategy. In the U.S. healthcare market the role of the pharmacist is changing. This report details the tremendous transformation occuring. |
|
| Drug pricing is one of the key levers that determine the profitability of a drug company. Premium pricing of a new drug helps cover the high cost of innovation and helps run a profitable enterprise. But the recent onslaught of generics, as well as shrinking government and corporate healthcare budgets, is threatening the time-tested models, leading to higher pricing pressures for pharmaceutical and biotech companies in the coming years. In this environment, executives in these companies and the consultants who service them need better information to make the most profitable decisions. |
|
| Orthopedic biomaterial products, which can be organic or synthetic in nature, are implanted into or near a bone fracture to facilitate healing or to compensate for a lack or loss of bone tissue. Biomaterials used in orthopedic surgery include autografts, allografts, xenografts, ceramics, polymers, bone growth factors and synovial fluid substitutes. Among the prominent applications for orthopedic biomaterials are surface coatings for hip prostheses, bone cements, bone defect fillers, and fracture fixation plates. |
|
| There are millions of surgical procedures performed annually worldwide and the market for wound care products and techniques is significant. In the United States alone, there are over 100,000 surgeries performed daily. Surgical and trauma wounds are, by far, the most common types of wounds addressed in the wound care area. |
|
| The aging of the population and continued advances in biotechnology drive the multi-billion dollar wound care industry globally. Besides the always-improving synthetic dressing materials, newer technologies in wound treatment include the xenogeneic tissue scaffold, bilayered human dermal substitutes, recombinant growth factors, endoscopic subfascial ligation of venous perforators, and endovascular arterial repair techniques. |
|
| The world market for OEM Contracting in the Manufacturing of Medical Devices is exploding as original equipment manufacturers are finding new opportunities with managers located at the corporate headquarters or main manufacturing/assembly operations continually reviewing manufacturing costs and looking to outsourcing for cost efficiency. |
|
| This Kalorama Information report - Clinical Nutrition Products: The World Market, represents the second time that Kalorama Information has taken a comprehensive look on the medical nutrition market in three segments:Infant Nutrition Enteral Nutrition Parenteral Nutrition |
|
| The unrecognized importance, danger and costs of hepatitis in the 21st century cannot be understated or underestimated. While we were fortunate that, in the latter part of the 20th century, in that hepatitis was fairly well held in check, the impact of the disease on world society is still highly significant and now presenting a major crisis in public health circles. |
|
| The use of virtual reality (VR) technologies in the healthcare field is not simply a far-away future possibility. Technologies are already in place and the benefits from the application of VR are already evident in the healthcare domain. These applications provide doctors an opportunity to perform tasks in a risk-free environment, and make training accessible for a large number of students as the apprenticeship of experienced doctors is not necessary. Additionally, VR simulators allow medical professionals to remain abreast with the latest technical procedures required in the profession. |
|
| The number of procedures requiring anesthetic administration continues to climb with the growing and aging population in many regions of the world. The population of the world plays an important role in the growing incidence and prevalence of disease and will reflect positively on growth for anesthesia drugs. |
|
| The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. |
|
| In light of laboratory pressures to do more with less, laboratory managers transfer cost control onto vendors by means of a constant push for price reductions. In this commercial climate, efficient management of customer and technical service extras is critical. Expertise in managing service offerings will help companies offer service programs that are just enough to differentiate them from the competition. Service programs that offer too much may result in revenue loss. Programs that are perceived to be inadequate place the company at a competitive disadvantage. |
|
| DNA sequencing can be defined as any biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, (A,G,C,T) in a DNA nucleotide. DNA Sequencing has accelerated research and discovery, which created a brisk market for sequencing systems that perform this work. That market has been relatively stable for the last several years, with a dominant vendor, Applied Biosystems, and relatively few changes taking place in the products or technologies. |
|
| Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life. The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. |
|
| Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that was measured after a drug was developed. Traditional studies were performed in-vivo with animals, and required 20 to 100 grams of the candidate compound for a single set of evaluations. Intake of the compound was measured, and a series of toxicity tests were performed, including LD 50 and histological examinations of target organs. These tox tests were expensive, time-consuming and were only performed on drug candidates that had already passed all other criteria to become successful drugs. These studies were high information, but low throughput estimates of a candidate drug’s toxicology. Failures were common, and expensive. The goal was to find approaches that would predict toxicology at an earlier stage, and with less cost. |
|
| The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, Over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. In addition to the basic pathology and complications of tuberculosis, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (tuberculosis patient trends) and technology. |
|
| RFID (Radio Frequency IDentification) technologies are dramatically changing many industries, but as detailed in Kalorama's market research report RFID Opportunities in Healthcare in the U.S., the greatest market for RFID is in healthcare. Hospitals, pharmaceutical companies, nursing homes, and other healthcare entities will benefit from using the technologies to keep track of inventories and patients. |
|
| Although Asia Pacific was the smallest healthcare market as of 2006, out of the three major geographic regions (US, Europe, and Asia Pacific), continued growth makes it an important ancillary market for makers of medical devices. |
|
| This study U.S. Market for Home Care Products, 5th Edition represents the fifth time Kalorama Information has investigated this growing market over the past 12 years. The U.S. market for home care products and equipment continues to post steady gains, primarily as a result of the aging population and increasing shifts of chronic care patients from hospitals to home. Serious market watchers will want to keep aware of trends in this industry, movers and shakers as well as market data. |
|
| Many in the clinical and manufacturing community have their eyes on the Physician Office Laboratory (POL) as an outlet both to improve patient compliance and outcomes and to open new market opportunities. Studies are emerging on the clinical outcomes and cost-benefit of nearer-the-patient testing, but little certain is known about POLs as a distribution channel for diagnostics products. |
|
| Molecular imaging maps the locations of specific molecules and biomaterials within living tissue. As such, it has the potential to diagnose a disease, to monitor the course of that disease, and possibly facilitate treatment. Molecular imaging has developed into a promising new strategy for the diagnosis, evaluation and treatment of disease. |
|
| This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic competition. Antifungals Antibacterials Antivirals As part of its comprehensive coverage, each report includes: Epidemiology including Incidence Statistics for each type of infection. Current Market Size and Revenue Forecasts for each market segment to assist with long term planning. Discussion of Competitive Products in the market and new products in the delivery pipeline. Coverage of Generic Threats for affected major products. Round-Up of the Key Players in each area of anti-infectives. Over 195 Tables and Figures for easy access to information and decision support tools, internal emails, memos and presentations. Discussion of Unique Issues and Emerging Trends for each antibiotic area. Market Share of Leading Competitors for each area. U.S., Europe, Japan and Rest of World market data. Product managers, marketing directors, business development executives in the pharmaceutical industry and financial and consulting company executives who invest in or serve this industry are among those who will find this report a useful resource. |
|
| This third volume of Kalorama Information’s World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease Inhibitors Other Misc. Antivirals The report covers both currently marketed and late stage development antiviral products in detail. For each segment, the report provides: Revenue Data by Infection Type An overview of products on the market Review of products in the development pipeline Market estimates and forecasts through 2011 Market segmentation by geographic region Market share of leading suppliers Market share of leading products The report also includes statistical (epidemiologic and demographic) information for viral infections by type worldwide, with special emphasis on the United States and describes the major clinical, business, and regulatory trends shaping the global and domestic markets. The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. In addition, Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. |
|
| Cancer is the second most common cause of death in the industrialized world. At this time, treatment for cancer focuses on some combination of surgery, radiation, and chemotherapy. But over the next five years, treatment is going to dramatically change. as detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market from Kalorama Information. One of the most promising new approaches in modern cancer treatment is immunotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. Immunological and biotherapy treatments which target therapy are a fraction of total cancer treatment revenues at the current time, but will soon make up the lion’s share of the total cancer therapy market. |
|
| New biological treatments are being developed at a record place, but their potential could be compromised by significant obstacles to delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. New systems are being developed, and Kalorama's Drug Delivery Markets Series covers these new systems. |
|
| Part of a three volume series. Over one billion people suffer from fungal infections worldwide. Although athlete's foot, dandruff, vaginal yeast infection and fungal nail are the most common, there has been a steady increase in the incidence of more serious infections. This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. Another has been the increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry. |
|
| This report includes all four volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal |
|
